Turkish Journal of Medical Sciences
Volume 28

Number 4

Article 19

1-1-1998

Plasma Fibronectin and UrineGlycosaminoglycane Levels in
Rheumatic Diseases
Nuriye METE
Mahmut METE
İ. Hakkı ÖZTÜRK
Leyla ÇOLPAN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
METE, Nuriye; METE, Mahmut; ÖZTÜRK, İ. Hakkı; and ÇOLPAN, Leyla (1998) "Plasma Fibronectin and
UrineGlycosaminoglycane Levels in Rheumatic Diseases," Turkish Journal of Medical Sciences: Vol. 28:
No. 4, Article 19. Available at: https://journals.tubitak.gov.tr/medical/vol28/iss4/19

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Tr. J. of Medical Sciences
28 (1998) 437-441
© TÜBİTAK

Nuriye METE1
Mahmut METE2
İ. Hakkı ÖZTÜRK1
Leyla ÇOLPAN1

Plasma Fibronectin and Urine
Glycosaminoglycane Levels in Rheumatic Diseases

Received: March 27, 1998

Abstract: In this study, plasma fibronectin
and urine glycosaminoglycane levels were
determined spectrophotometrically in 20
Rheumatoid arthritis, 10 Ankilosing
spondilites, 22 osteoarthrosis and 21 healthy
control subjects. The mean levels of
Fibronectin (µg/ml) were 413.3±97 in
patients with rheumatoid arthritis,
325.5±93.5 in ankilosing spondilites,
439.1±120.3 in osteoarthrosis and
302.2±60.1 in the control group. The ratio
of urine glycosaminoglycan excretion to
creatinine (g/mol) was 4.52±2.64 in patients
with rheumatoid arthritis, 4.18±1.52 in
patients with ankilosing spondilites,
2.72±1.19 in osteoarthrosis and 2.21±1.02
in the control group. Plasma Fibronectin
levels were significantly higher in rheumatoid
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Introduction
Rheumatoid Arthritis (RA), Ankilosing Spondilites
(AS) and Osteoarthrosis (OA) are multy-systemic
connective tissue diseases. Fibronectin (FN) and
Glycosaminoglycans (GAGs) are structural components of
this tissue and they have important physiological and
biochemical duties (1-10). To dates, there are a number
of investigations have been hold for the diagnosis of
R.diseases. It is thought that plasma FN and urine GAGs
might be in these investigations, while they are the
compound of the connective tissue.
So we investigate whether these connective tissue
inter-components would help the diagnosis in determining
degenerative changes, and to reveal their importance in
distinguishing R.diseases and their follow up as well as
the correlation between plasma FN level and urinary GAG
excretion.
Material and Methods
In this study, plasma FN and urine GAG levels of 21

arthritis and osteoarthrosis when compared
to the control group (p<0.001). The ratio of
urinary glycosaminoglycans excretion to
creatinine levels in patients with rheumatoid
arthritis and ankilosing spondilites were
significantly greater when compared with
control group (p<0.001).
Having established that plasma fibronectin
levels
and
urine
glycosaminoglycane/creatinine ratio were
important laboratory findings in rheumatic
diseases, and it was decided to employ
further research to englihten mechanisms
that are still controversial.

Key Words: Rheumatic disease, fibronectin,
glycosaminoglycane.

healthy subjects and 52 cases, 20 of whom were with RA,
10 with AS and 22 with OA, were determined. 17 of the
RA cases were female, 3 were male, 1 of the AS cases
was female, 9 were male and 18 of the OA cases were
female, 4 were male. The mean age of the patients for
RA, AS and OA were 40.6±5, 25.8±7.4, 52±7.5
respectively. The definite diagnosis of the patients’ group
was accomplished by evaluating clinical findings,
radiologic examinations and ARA (American Rheumatism
Association) criteria (11, 12). In addition, laboratory
examinations such as liver and renal function tests, Creactive protein, rheumatoid factor (RF), eritrosit
sedimentation rate (ESR), the whole blood and urine. By
taking ESR into consideration, the group with RA was
divided into sub-groups according to their activities. (L-5
case, M-6 case, H9 case). The all AS cases are in active
stage.
The control group was formed from among
individuals in whom no degenerative changes seen by
arthregraphy and in whom blood analyses were normal.
Together with the first urinary samples in the
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Variables

Control
(n=21)

RA
(n=20)

AS
(n=10)

OA
(n=22)

F

P

Age
Fibronectin
(µg/ml)
Urine GAG/
Creatinine
(g/mol)

37.05±8.04

40.60±11.25

25.80±21.50

51.68±7.4

23.2
9.27

0.00001
0.00001

302.2±60.1

413.3±97.0

325.5±93.5

439.1±120.3
8.26

0.0001

2.21±1.02

4.52±2.64

4.18±1.52

2.72±1.19

Variables

RA.L
(n=5)

RA.M
(n=6)

RA.H
(n=9)

F

P

2.71±0.96

3.87±1.8

5.48±3.02

5.03

<0.001

365±60.1

401±98.7

424±106

2.01

>0.05

Urine GAG/
Creatinine
(g/mol)
Plasma FN
(µg/ml)

Table 1.

The statistical values of
parameters measured in plasma
and urine.

Table 2.

Comparision
of
urine
GAG/Creatinine and plasma FN
levels in the cases with RA
according to their activity.

Cases with RA were divided into 3 activity groups according to ESR;
RA.H: 61-125 mm/h
RA.M: 41-60 mm/h
RA.L: Under 40 mm/h
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Figure 2. The mean values of plasma FN levels in all cases

OA

Figure 1. Distrubition of plasma FN levels in all groups.

morning, the blood samples with venous EDTA were
taken simultaneously from the cases.
Plasma FN level was determined by turbidimetric
immunoassay method, using Manheim Boehringer Kit
(Cat No:401218).
Urine GAG level was determined by spectrofotometric
method, based upon the staining of GAGs with cationic
dyes (1, 9 dimethyl methylen Blue) (13) and urine
creatinine was measured by an autoanalyzer.
Results were evaluated by SPSS computer
programme. Analysis of variance was performed for the
detection of significance of difference between groups.
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Tukey-HSD procedure was used to investigate between
which groups the difference was observed. Significance
level was taken as 0.05 for Tukey-HSD procedure.
Findings
1- The mean plasma FN level was 413.3±97 µg/ml in
patients with RA, 325.5±93.5 µg/ml in patients with AS,
439.1±120.3 µg/ml in those with OA, while it was
measured as 302.2±60.1 µg/ml in the control group. The
difference between the all groups was significant
according to analysis of variance (F=9.27) (p<0.00001).
According to Tukey-HSD procedure, the plasma FN level
was significantly different between AS and OA, control
and RA, control and OA groups (p<0.05) (Table 1) (Fig.
1, 2).
2- In order to diminish the changes that would arise
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Table 3.

Variable

Fibronectin

Urine GAG/Creatinine

RA-AS

413.3±97

325.5±93.5*

4.52±2.64

4.18±1.52

RA-OA

413.3±97

439.1±120.3

4.52±2.64

2.72±1.19***

AS-OA

325.5±93.5

439.1±120.3***

4.18±1.52

2.72±1.19**

The statistial comparision of
parameters between patient
groups.

*P<0.05
**P<0.02
***P<0.01

analysis of variance (F=8.26) (p<0.0001). According to
Tukey-HSD procedure, excretion of GAG in urine was
significantly different between RA and OA, control and
RA, control and AS groups (p<0.05) (Table 1) (Figure 3,
4).
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3- Among the groups divided as Low (L, 5 case),
Medium (M, 6 case) and High (H, 9 case) according to
their activities by taking ESR into account. A significant
difference only between urinary GAG excretions of highand low-activity RA groups was observed (Table 2).
4- In all patient groups, any significant correlation
between plasma FN level and GAG excretion through
urine was not determined (in RA, AS and OA, r=0.273,
r=0.485 and r=0.118, respectively). Between the age
and FN levels of patients, marked correlation in patients
with AS was observed (r=0.823 p<0.01).
Discussion
Fibronectin levels:

5
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Figure 4. The mean values of urine GAG/creatinine ratios in all cases.

from liquid and excretion, urinary GAG values was
evaluated by proportioning them with creatinine, as did
other researchers. When the ratio of GAG to creatinine
was measured, it was found to be 2.21±1.02 as an
average of g/mol in the control group. This ratio was
4.52±2.64 in patients with RA, 4.18±1.52 in those with
AS, 2.72±1.19 in patients with OA. The difference
between the all groups was significant according to

In this study, plasma FN levels in OA and RA were
found to be higher than those in the control group
(p<0.001). However, any significant difference was not
seen among the findings of patients with RA, divided into
groups according to their activities. Even though present
results were in agreement with findings of others (1418), there were also studies that were opposite to our
findings (19, 20). Another interesting finding was that
FN was lower in those with connective tissue disease.
Besides a number of cells, FN is synthesized in
chondrocytes (16) and synovial cells. It plays an
important role in joint inflamations and pannus extention,
since it is an opsonic and chemotactic agent (1, 3). It has
been demonstrated that FN is synthesized in neutrofils
and in Type-B synovitis in rheumatic diseases (3). It has
also been reported that synovial fluid FN fragments
increase, and that this does not stimulate synovial
proliferation, however (21). When the role of fibronectin
fragments in the progress of inflamation was
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investigated, it was explained that they are reacted with
antibodies arising from streptococcus infections, and that
these immune complexes have a role in the RA etiology
(22).
In a study in which synovial fluid FN-mRNA level was
investigated, the increase in FN was ascribed to the
increase in the number of cells synthesizing protein,
rather than to the arrangement of genes (10). They have
reported that FN-mRNA levels in patients with RA, OA
and AS vary, and that they, however, have not any
relationship with the diagnosis of the disease and cell
infiltration (10). Data obtained in the present study
indicated that no differences between patients with AS
and control group. This suggestion is confirmed by others
finding (16, 17, 18, 21).
Low FN levels may be due to two reasons in cases with
AS. One of the two reasons is that the disease involves the
vertebral ligaments and synovial space is not wide enough
because the peripheral tissue does not participate the
process. The other reason is approach to terminal stage
of the disease after ligamentary ossification completed
(16, 18). However synovial tissue participates the
process as polyarticularly in RA. Synovity of all joints is
started and then continue with activations joints
occurence of arthrosis in rick from synovial tissue in OA
results with progression of secondary synovitis (16, 18,
21).
From these study we suggest that: FN levels increase
in patients with RA and OA, while not in those with AS.
In order to form complete picture of this event, it will be
necessary to look at other aspects such as molecular
basis.
GAG excretion with urine
In our study, it was seen that the ratio of urine
GAG/creatinine in patients with RA and AS increased
significantly in respect to control group. However, there
was not any different change in patients with OA. This
finding was encountered only in one study (6).

In other studies carried out, increase of GAG in
synovial liquid, serum and urine in various rheumatic
diseases was reported (6, 23). Urine GAG measurement
is a useful index that determines activity (6). Chondrocyte
proliferation and damage have been reported as the
reason for the increase in urinary GAG excretion. The
changes observed in the PG content of tissue constitute
the main part of pathophysiology of the disease (11).
Increase in GAG excretion fragmentation occurs
during acute phase of reactive arthritis (8). In further
stage of the disease, progressive destruction of matrix is
prevented by the development of restructive mechanism.
The role of GAGs in identifying the degree of cartilage
damage in arthritis has been investigated, according to
which, when cartilage damage progresses, it has been
seen that the hyaluronan-binding site of proteoglicans is
more dominant than the site rich in GAGs (8).
In this study, it was seen that GAG excretion through
urine was more significant in the active state of RA. The
recognition of the RA activity is important in determining
the response of the drug to the disease. Another
important finding was that there was not any relationship
between plasma level and urinary excretion in all patient
groups. Releasing and using mechanisms of these
compounds which are connective tissue compounds
should be investigated more comprehensively.
Data presented in this study suggest that
determination of urinary GAG excretion might be an
important parameter in inflamatory diseases of arthrosis
progressing with matrix destruction, especially in the
diagnosis and follow-up of RA and AS.
In addition; the diagnosis of R. patients indicated that
plasma FN level is significant together with other
parameters, but investigating Its’ importance in the
etiopathogenesis of the disease.
Results generated in this study also indicated that
more comprehensive studies are required related to the
role of synovial FN fragments in the progress of the
disease.
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